Results 21 to 30 of about 4,524 (132)

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways. [PDF]

Br J Haematol
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Kashyap T, Ellero AA, Walker CJ, Maloof ME, Lu M, Xia L, Hoffman R, Taverna P.   +7 more
europepmc   +2 more sources

The Combination of Allele Burden and Expression can Be Helpful in Distinguishing the Subtype of MPN Patients

Cancer Control, 2023
Introduction Classical Philadelphia-negative myeloproliferative neoplasm (MPN) includes Essential Thrombocythemia (ET), Polycythemia Vera (PV) and Primary Myelofibrosis (PMF). The JAK2V617F mutation is part of the major criteria for diagnosis of MPN. WT1
Sanyun Wu, Ping Luo, Tuerxunayi Rouzi, Yalan Yu, Bei Xiong, Yingying Wang, Xuelan Zuo   +6 more
doaj   +1 more source

TYK2 is essential for the therapeutic effect of IFN-α in Jak2V617F-induced murine myeloproliferative neoplasms

Blood Neoplasia
: Interferon-α (IFN-α) exhibits antiviral and antiproliferative effects on normal and neoplastic cells. Intracellular signaling of IFN-α is mediated by tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1), followed by signal transducers and activators of ...
Yuki Tahira, Kotaro Shide, Takuro Kameda, Taisuke Uchida, Ayako Kamiunten, Keiichi Akizuki, Yoko Kubuki, Masayoshi Karasawa, Ryoma Ikeda, Kengo Matsumoto, Jie Bai, Minoru Terashima, Koji Kato, Tomofumi Uto, Tomohiro Fukaya, Shuya Mitoma, Katsuaki Sato, Yudai Uehira, Hiroaki Ueno, Goro Sashida, Hideki Yamaguchi, Kazuya Shimoda   +21 more
doaj   +1 more source

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms

Blood Advances, 2017
: High-mobility group AT-hook 2 (HMGA2) is crucial for the self-renewal of fetal hematopoietic stem cells (HSCs) but is downregulated in adult HSCs via repression by MIRlet-7 and the polycomb-recessive complex 2 (PRC2) including EZH2. The HMGA2 messenger
Koki Ueda, Kazuhiko Ikeda, Takayuki Ikezoe, Kayo Harada-Shirado, Kazuei Ogawa, Yuko Hashimoto, Takahiro Sano, Hiroshi Ohkawara, Satoshi Kimura, Akiko Shichishima-Nakamura, Yuichi Nakamura, Yayoi Shikama, Tsutomu Mori, Philip J. Mason, Monica Bessler, Soji Morishita, Norio Komatsu, Kotaro Shide, Kazuya Shimoda, Shuhei Koide, Kazumasa Aoyama, Motohiko Oshima, Atsushi Iwama, Yasuchika Takeishi   +23 more
doaj   +1 more source

Rapid identification of heterozygous or homozygous JAK2V617F mutations in myeloproliferative neoplasms using melting curve analysis

Journal of the Formosan Medical Association, 2012
The activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2V617F) is associated with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis.
Ching-Liang Ho, Yi-Ying Wu, Hsiu-Man Hung, Ping-Ying Chang, Wei-You Kao, Yeu-Chin Chen, Tsu-Yi Chao   +6 more
doaj   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability

Cell Reports, 2015
JAK2V617F is the most common oncogenic lesion in patients with myeloproliferative neoplasms (MPNs). Despite the ability of JAK2V617F to instigate DNA damage in vitro, MPNs are nevertheless characterized by genomic stability.
Edwin Chen, Jong Sook Ahn, David B. Sykes, Lawrence J. Breyfogle, Anna L. Godfrey, Jyoti Nangalia, Amy Ko, Daniel J. DeAngelo, Anthony R. Green, Ann Mullally   +9 more
doaj   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Association between JAK2V617F Mutation and Mean Platelet Volume among Myeloproliferative Neoplasm Patients

Journal of Applied Hematology
BACKGROUND: Myeloproliferative neoplasms (MPNs) are clonal disorders affecting myeloid progenitor cells, with thrombotic events being a major cause of mortality and morbidity. Increased mean platelet volume (MPV) has been linked to higher thrombosis risk.
Mushtaq M. Khazeem, Alaa Fadhil Alwan
doaj   +1 more source

Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F+ myelofibrosis

Frontiers in Genetics, 2022
Objective: This study aimed to identify specific dysregulated genes with potential diagnostic and predictive values for JAK2V617F+ myelofibrosis.Methods: Two gene expression datasets of CD34+ hematopoietic stem and progenitor cells (HSPCs) from patients ...
Yanhong Zhao, Di Wang, Yipeng Liang, Changlu Xu, Lihong Shi, Jingyuan Tong   +5 more
doaj   +1 more source